ICF has secured two new multiyear contracts worth about $70 million to implement energy efficiency programs for the Southern California Regional Energy Network (SoCalREN). These programs aim to reduce energy costs, enhance grid reliability, and support public agencies in deploying energy-saving and distributed energy projects. ICF will leverage its technology and expertise to target high-demand areas and improve community energy outcomes across Southern California. This expansion builds on ICF's decade-long partnership with SoCalREN to increase energy savings and program participation.
The new energy efficiency contracts awarded to ICF provide context for the energy sector's performance on Pluang. For readers following the energy sector, here is Pluang's market snapshot as of Sep 29, 2026 02:11 WIB: Of 38 priced US energy stocks, 16 rose and 22 fell. Occidental Petroleum Corporation (OXY) traded at USD 56.16 with a 1-day change of -1.24% and a typical hold time of 91 days, while Ecopetrol SA (EC) was priced at USD 16.79, up 1.24% with an 84-day hold time. Cenovus Energy Inc (CVE) stood at USD 31.29, rising 1.16% with a shorter typical hold time of 46 days.
Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...
H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...
Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...
Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...
Neurocrine Biosciences announced that Eiry W. Roberts, M.D., has rejoined as Chief Medical Officer, replacing Sanjay Keswani by mutual agreement. Dr. Roberts previously served as CMO from 2018 to 2025 and has been a Strategic Advisor since. Her retur...
